Year: 2025
Type: article
Abstract: The lung cancer treatment landscape is rapidly evolving, with advances extending across non-small cell lung cancer (NSCLC), pleural mesothelioma and small cell lung cancer (SCLC). Immune checkpoint inhibitors (ICIs), targeted therapies and novel combination regimens offer new hope for patients with thoracic malignancies and are reshaping standards of care. At the European Lung Cancer Congress (ELCC 2025), the Swiss Cancer Institute (formerly SAKK) presented its research across disease subtypes, including the final results from the phase II trial SAKK 16/14 investigating perioperative durvalumab in combination with neoadjuvant chemotherapy in patients with resectable stage IIIA(N2) NSCLC and findings from the phase II trial SAKK 17/18 ORIGIN investigating gemcitabine combined with atezolizumab in patients with pleural mesothelioma. The Swiss Cancer Institute is also contributing to several collaborative group trials, including ETOP AMAZE-lung investigating amivantamab plus lazertinib and bevacizumab in EGFR-mutant NSCLC post-osimertinib, ETOP 25-23 ADOPT-lung evaluating neo-adjuvant versus peri-operative durvalumab in patients with resectable NSCLC and a real-world analysis of extensive-stage (ES)-SCLC molecular subtypes and clinical outcomes. This article summarizes key data from these relevant clinical studies. Received on June 18, 2025; accepted after peer review on October 05, 2025; published on October 13, 2025. PEER REVIEWED ARTICLE **Peer reviewers:** Prof. Daniel Betticher, Clinic of Medical Oncology, Cantonal Hospital of Fribourg, Fribourg, Switzerland One anonymous peer reviewer
Authors: Sacha I. Rothschild, Christine Waibel, David König, Stefanie Hayoz, Laetitia A. Mauti
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4415464666
FWCI:
Cites:
Cited by:
Related to: